GLP-1 drugs have been shown to have cardiovascular benefits, such as a reduced risk of heart attacks and strokes in people with type 2 diabetes
There are four GLP-1 agonist medicines approved by the Therapeutic Goods Administration (TGA) for use in Australia for the management of Type 2 Diabetes: dulaglutide ( Trulicity ) semaglutide ( Ozempic ) tirzepatide ( Mounjaro ) liraglutide ( Saxenda )
GLP-1 receptor agonists in PD Approved treatments for PD target dopaminergic neurotransmission, with levodopa representing the mainstay of treatments augmenting dopamine production and alleviating motor symptoms [6]
Gastrointestinal Side Effects: GLP-1 medications often cause side effects like nausea, vomiting, or acid reflux [3]
Studies show: Lowering inflammation with GLP-1s can slow the rate of joint damage in RA If you have RA and obesity or diabetes, takingGLP-1 meds can mean fewer flares and less need for extra medicine
This helps explain why payer coverage restrictions for GLP-1s used for obesity continue to be a hurdle for patients who seek access
